MUMBAI, India, Aug. 31 -- Intellectual Property India has published a patent application (202641101270 A) filed by Dr. Jagadeeswari Sridharan; Dr. Kirthiga Bharathidasan; Dr. Rajalakshmi Velmurugan; Dr. Abirami Mariappan; Dr. Nisha Joginder; and Dr. Anusha Shree Krishnamurthy on August 21, 2026, for Bacteriophage-Based Targeted Antimicrobial System For Selective Elimination Of Multidrug-Resistant Bacteria.
Inventors include Dr. Jagadeeswari Sridharan; Dr. Kirthiga Bharathidasan; Dr. Rajalakshmi Velmurugan; Dr. Abirami Mariappan; Dr. Nisha Joginder; and Dr. Anusha Shree Krishnamurthy.
The application for the patent was published on August 28, 2026, under issue no. 35/2026.
Abstract: ABSTRACT Bacteriophage-Based Targeted Antimicrobial System for Selective Elimination of Multidrug-Resistant Bacteria The present invention relates to a bacteriophage-based targeted antimicrobial system configured for selective identification and elimination of multidrug-resistant (MDR) bacterial populations while minimizing disruption to beneficial microbial communities. The system comprises one or more bacteriophages selected for specificity toward predetermined bacterial targets, a target-identification module configured to characterize bacterial species, strains, or resistance-associated biomarkers, and a controlled delivery platform configured to administer the bacteriophage composition to a target environment. In certain embodiments, the system employs a computational selection module that analyzes bacterial identification data, antimicrobial resistance profiles, and bacteriophage–host compatibility information to determine an appropriate bacteriophage or bacteriophage combination. The selected bacteriophages may be formulated individually or as a multi-phage composition to address bacterial heterogeneity and reduce the likelihood of therapeutic escape. The system may further include encapsulation, stabilization, or localized-release components that improve bacteriophage persistence and targeted exposure. A monitoring module may assess bacterial reduction, changes in target abundance, and emergence of reduced bacteriophage susceptibility, thereby enabling selection or adjustment of an alternative bacteriophage composition. The invention can be configured for applications involving healthcare-associated infections, wound-associated bacterial infections, environmental decontamination, food-associated contamination, veterinary applications, and other settings in which selective reduction of resistant bacteria is desirable. By integrating bacterial recognition, bacteriophage selection, targeted delivery, and response monitoring into a coordinated platform, the proposed invention provides a selective antimicrobial approach intended to complement or reduce reliance on conventional broad-spectrum antimicrobial agents.
Disclaimer: Curated by HT Syndication.
